CD1D and lymphoma: Additionally, CD19-specific NKT cells were found to be more effective than CD19-targeting CAR-T cells against CD1d-expressing lymphomas in vitro and in vivo, suggesting CAR-NKTs can provide unique advantages in treating lymphomas and other CD1d-expressing tumors [111].